Deals

Boehringer Ingelheim and Sino Biopharmaceutical Forge Strategic Multi‑Project ADC and TCE Option Deal – $358 Million Upfront, Up to $7 Billion in Milestones Across Six Preclinical Cancer Programs
ADC / XDCBoehringer Ingelheim

Boehringer Ingelheim and Sino Biopharmaceutical Forge Strategic Multi‑Project ADC and TCE Option Deal – $358 Million Upfront, Up to $7 Billion in Milestones Across Six Preclinical Cancer Programs

Boehringer Ingelheim and Sino Biopharmaceutical (HKG: 1177) announced that they have entered into a strategic multi‑project option and license agreement to advance potential next‑generation cancer treatments based on antibody‑drug conjugate…

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment
Innovative Cellular TherapeuticsLyell Immunopharma

Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment

Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005
Brise PharmaceuticalsFinance

Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005

MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4
Eli LillyGene therapy

MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines
BiotechCanSino Biologics

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines

Show More